First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration
First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration
Recruiting · NCT07269665 · Registry updated 2026-08-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration | Bardet-Biedl syndrome 1, Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Recruiting | Early phase 1 | 2026-08-04 | NCT07269665 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Axovia Therapeutics | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Moorfields Eye Hospital | London | United Kingdom | 14 |